Lyell Immunopharma (LYEL)

• Market cap: $318M
• 1 day: 3.7%
• 5 days: -0.3%
• 1 month: -7.34%
• 3 months: 44.71%
• 6 months: 90.33%
• Year to date: 28.22%
• 1 year: -33.31%
• 5 years: -95.1%
• 10 years: -95.1%
• Sector: Healthcare
• Industry: Biotechnology

About: Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others.

Employees: 300